102 related articles for article (PubMed ID: 30358274)
21. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
Li X; Zhu L; Zhou C; Liu J; Du H; Wang C; Fang S
PLoS One; 2018; 13(3):e0194501. PubMed ID: 29558528
[TBL] [Abstract][Full Text] [Related]
22. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
Raskin J; Xu JY; Kajdasz DK
Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
[TBL] [Abstract][Full Text] [Related]
24. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
[TBL] [Abstract][Full Text] [Related]
25. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
26. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
27. Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.
Shi N; Cao Z; Durden E; Schacht A; Torres A; Happich M
J Med Econ; 2012; 15(4):672-80. PubMed ID: 22390770
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Müller N; Schennach R; Riedel M; Möller HJ
Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
[TBL] [Abstract][Full Text] [Related]
29. Methodological approach to brain-derived neurotrophic factor plasma levels in major depressed patients receiving duloxetine.
Agilli M; Aydin FN
Neurol Sci; 2015 Jun; 36(6):1061-2. PubMed ID: 25637063
[No Abstract] [Full Text] [Related]
30. Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain.
Kim NY; Lee SC; Kim YW
Clin Neuropharmacol; 2019; 42(3):73-76. PubMed ID: 31085946
[TBL] [Abstract][Full Text] [Related]
31. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of patient education and duloxetine, alone and in combination, for patients with multisystem functional somatic disorder: Study protocol for the EDULOX trial.
Jespersen CP; Pedersen HF; Kleinstäuber M; Fink P; Wellnitz KB; Ørnbøl E; Schröder A; Agger JL; Vase L; Finnerup NB; Gormsen LK
Contemp Clin Trials; 2024 Jun; 141():107524. PubMed ID: 38604496
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.
Maciukiewicz M; Marshe VS; Tiwari AK; Fonseka TM; Freeman N; Rotzinger S; Foster JA; Kennedy JL; Kennedy SH; Müller DJ
Pharmacogenomics; 2015 Nov; 16(17):1919-29. PubMed ID: 26556688
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of Persistent Somatoform Pain Disorder by Floating Needle Therapy and Duloxetine].
Ren WW; Zhou ZY; Xu MM; Long S; Tang GZ; Mao HJ; Chen SL
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Feb; 36(2):166-71. PubMed ID: 27078991
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
36. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
37. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials.
Zhang Y; Huang G; Yang S; Liang W; Zhang L; Wang C
Asia Pac Psychiatry; 2016 Sep; 8(3):215-25. PubMed ID: 26238298
[TBL] [Abstract][Full Text] [Related]
39. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
40. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Karaiskos D; Tzavellas E; Spengos K; Vassilopoulou S; Paparrigopoulos T
J Neuropsychiatry Clin Neurosci; 2012; 24(3):349-53. PubMed ID: 23037649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
